Application of Static Modeling --in the Prediction of In Vivo Drug-Drug Interactions between Rivaroxaban and Antiarrhythmic Agents Based on In Vitro Inhibition Studies - PubMed

Affiliations

• PMID: 28053220
• DOI: 10.1124/dmd.116.073890

Application of Static Modeling --in the Prediction of In Vivo Drug-Drug Interactions between Rivaroxaban and Antiarrhythmic Agents Based on In Vitro Inhibition Studies

Eleanor Jing Yi Cheong et al. Drug Metab Dispos. 2017 Mar.

Abstract

Rivaroxaban, a direct Factor Xa inhibitor, is indicated for stroke prevention in nonvalvular atrial fibrillation (AF). Studies have revealed that the clearance of rivaroxaban is largely attributed to CYP3A4, CYP2J2 metabolism, and P-glycoprotein (P-gp) efflux pathways. Amiodarone and dronedarone are antiarrhythmic agents employed in AF management. Amiodarone, dronedarone, and their major metabolites, N-desethylamiodarone (NDEA) and N-desbutyldronedarone (NDBD), demonstrate inhibitory effects on CYP3A4 and CYP2J2 with U.S. Food and Drug Administration-recommended probe substrates. In addition, both amiodarone and dronedarone are known P-gp inhibitors. Hence, the concomitant administration of these antiarrhythmic agents has the potential to augment the systemic exposure of rivaroxaban through simultaneous impairment of its clearance pathways. Currently, however, clinical data on the extent of these postulated drug-drug interactions are lacking. In this study, in vitro inhibition assays using rivaroxaban as the probe substrate demonstrated that both dronedarone and NDBD produced reversible inhibition as well as irreversible mechanism-based inactivation of CYP3A4- and CYP2J2-mediated metabolism of rivaroxaban. However, amiodarone and NDEA were observed to cause reversible inhibition as well as mechanism-based inactivation of CYP3A4 but not CYP2J2. In addition, amiodarone, NDEA, and dronedarone, but not NDBD, were determined to inhibit P-gp-mediated rivaroxaban transport. The in vitro inhibition parameters were fitted into a mechanistic static model, which predicted a 37% and 31% increase in rivaroxaban exposure due to the inhibition of hepatic and gut metabolism by amiodarone and dronedarone, respectively. A separate model quantifying the inhibition of P-gp-mediated efflux by amiodarone or dronedarone projected a 9% increase in rivaroxaban exposure.

Similar articles

• Multiple modes of inhibition of human cytochrome P450 2J2 by dronedarone, amiodarone and their active metabolites.

  Karkhanis A, Lam HY, Venkatesan G, Koh SK, Chai CL, Zhou L, Hong Y, Kojodjojo P, Chan EC. Karkhanis A, et al. Biochem Pharmacol. 2016 May 1;107:67-80. doi: 10.1016/j.bcp.2016.03.005. Epub 2016 Mar 10. Biochem Pharmacol. 2016. PMID: 26972388

• Effects of dronedarone, amiodarone and their active metabolites on sequential metabolism of arachidonic acid to epoxyeicosatrienoic and dihydroxyeicosatrienoic acids.

  Karkhanis A, Tram NDT, Chan ECY. Karkhanis A, et al. Biochem Pharmacol. 2017 Dec 15;146:188-198. doi: 10.1016/j.bcp.2017.09.012. Epub 2017 Sep 25. Biochem Pharmacol. 2017. PMID: 28958841

• Investigation of the arcane inhibition of human organic anion transporter 3 by benzofuran antiarrhythmic agents.

  Tan HL, Tang LWT, Chin SY, Chan ECY. Tan HL, et al. Drug Metab Pharmacokinet. 2021 Jun;38:100390. doi: 10.1016/j.dmpk.2021.100390. Epub 2021 Mar 20. Drug Metab Pharmacokinet. 2021. PMID: 33836300

• Clinical significance of the rivaroxaban-dronedarone interaction: insights from physiologically based pharmacokinetic modelling.

  Hügl B, Horlitz M, Fischer K, Kreutz R. Hügl B, et al. Eur Heart J Open. 2023 Jan 23;3(1):oead004. doi: 10.1093/ehjopen/oead004. eCollection 2023 Jan. Eur Heart J Open. 2023. PMID: 36820238 Free PMC article. Review.

• Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban.

  Stöllberger C, Finsterer J. Stöllberger C, et al. Herz. 2015 Apr;40 Suppl 2:140-5. doi: 10.1007/s00059-014-4188-9. Epub 2015 Jan 25. Herz. 2015. PMID: 25616425 Review.

Cited by

• Risk assessment and molecular mechanism study of drug-drug interactions between rivaroxaban and tyrosine kinase inhibitors mediated by CYP2J2/3A4 and BCRP/P-gp.

  Zhao T, Li X, Chen Y, Du J, Chen X, Wang D, Wang L, Zhao S, Wang C, Meng Q, Sun H, Liu K, Wu J. Zhao T, et al. Front Pharmacol. 2022 Aug 22;13:914842. doi: 10.3389/fphar.2022.914842. eCollection 2022. Front Pharmacol. 2022. PMID: 36071847 Free PMC article.

• Comprehensive Predictions of Cytochrome P450 (P450)-Mediated In Vivo Cannabinoid-Drug Interactions Based on Reversible and Time-Dependent P450 Inhibition in Human Liver Microsomes.

  Bansal S, Paine MF, Unadkat JD. Bansal S, et al. Drug Metab Dispos. 2022 Apr;50(4):351-360. doi: 10.1124/dmd.121.000734. Epub 2022 Feb 3. Drug Metab Dispos. 2022. PMID: 35115300 Free PMC article.

• DOAC drug interactions management resource.

  Chadha A, Guirguis M, Bungard TJ. Chadha A, et al. Can Pharm J (Ott). 2022 Sep 20;155(6):315-325. doi: 10.1177/17151635221116100. eCollection 2022 Nov. Can Pharm J (Ott). 2022. PMID: 36386604 Free PMC article. No abstract available.

• Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions: Research Methods and Applications.

  Sun L, Mi K, Hou Y, Hui T, Zhang L, Tao Y, Liu Z, Huang L. Sun L, et al. Metabolites. 2023 Jul 29;13(8):897. doi: 10.3390/metabo13080897. Metabolites. 2023. PMID: 37623842 Free PMC article. Review.

• Drug-Drug Interactions Leading to Adverse Drug Reactions with Rivaroxaban: A Systematic Review of the Literature and Analysis of VigiBase.

  Fernandez S, Lenoir C, Samer CF, Rollason V. Fernandez S, et al. J Pers Med. 2021 Mar 30;11(4):250. doi: 10.3390/jpm11040250. J Pers Med. 2021. PMID: 33808367 Free PMC article. Review.

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • scite Smart Citations

• Miscellaneous

  • NCI CPTAC Assay Portal